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1. Introduction 
Testosterone (T) therapy has been offered to men who have low T levels, who are symptomatic 
with classical androgen deficiency syndromes, to induce and maintain secondary sex 
characteristics and to improve muscle mass and strength, bone mineral density, their sexual 
function, and sense of well-being. Hypogonadism is a clinical syndrome that  is caused by 
inability of the testis to produce physiological levels of T in men. The age-related reduction in 
T levels is a result of defects in both hypothalamic-pituitary and testicular function. A 
diagnosis of androgen deficiency should be made only when low serum T and consistent 
symptoms and signs are encountered in men. It is not recommended to offer T therapy to all 
older men with low T level. A decision should be made on an individualized basis for older 
men with clinically significant symptoms of androgen deficiency and consistently low T level. 
Hyperandrogenemia in women and hypoandrogenemia in men are associated with increased 
risk of coronary artery disease. In addition, these states are associated with insulin resistance, 
visceral obesity, elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, low-
densitylipoprotein (LDL) cholesterol and plasminogen activator inhibitor (PAI-1). These 
gender differences and confounders make the exact role of endogenous androgens in 
atherosclerosis unclear. In contrast, exogenous androgens exert both apparently beneficial and 
deleterious effects on cardiovascular risk factors by reducing serum levels of PAI-1 (apparently 
deleterious), HDL-C, insulin, leptin, lipoprotein(a), visceral fat mass (apparently beneficial), 
and fibrinogen in women as well as men.  Androgen-induced reduction in circulating HDL-C 
levels should not reflexively be considered to be pro-atherogenic, because it may show 
increased reverse cholesterol transport instead. Short-term use of supraphysiological doses of 
exogenous T can decrease the severity and frequency of angina pectoris and reverse the 
electrocardiographic signs of myocardial ischaemia; yet long-term effects have not been 
determined. Nonetheless,  the effects of pharmacological doses of androgens particularly on 
flow-mediated dilatation and arterial compliance must be interpreted with caution, since in 
addition at physiological concentrations detrimental effects, neutral, and beneficial effects on 
vascular reactivity can be observed. Testosterone induces an anti-atherogenic  effect by 
facilitating  efflux of cellular cholesterol to HDL and induces pro-atherogenic effects on 
macrophage function by increasing the uptake of modified lipoproteins.  
2. Endogenous T and CAD morbidity\mortalitiy 
In half of cross-sectional studies [Wu and Eckardstein 2003; Alexandersen et al 1996], serum 
levels of T were lower in patients with CAD than healthy controls. The other half of the 
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studies demontrated no difference in T levels when cases and controls are compared. In 
none of the studies,  high levels of T  were seen in patients with CAD. In all the studies, an 
inverse association was found between CAD and levels of free T [Wu and Eckardstein 2003; 
Alexandersen et al 1996]. None of six longitudinal studies revealed any significant 
association between the future risk of CAD events and serum levels of T in men [Wu and 
Eckardstein, 2003; Alexandersen et al., 1996]. 
European Prospective Investigation into Cancer in Norfolk Study demonstrated that serum 
levels of T at baseline were inversely associated with cardiovascular mortality and all-cause 
mortality in men aged 40-79 with no history of cancer or cardiovascular disease (Khaw et al., 
2007). This risk association persisted after correction for traditional cardiovascular risk 
factors, indicating that the benefit may involve additional pathways. Also, other studies 
have showed the association between low testosterone and cardiovascular disease and 
increased mortality (English et al., 2000; Shores et al., 2006). Thus, increasing research on the 
clinical implications of physiological decline in androgens with aging has led to rekindled 
interest in the potentially cardioprotective role of T. Abuse of T is associated with increased 
risk of cardiovascular disease and sudden death, yet higher T serum levels within the 
physiological range have been associated with a more favourable cardio-metabolic risk 
profile. In contrast, low T serum levels have been associated with elevated triglyceride and 
low high-density-lipoprotein-cholesterol levels, glucose intolerance, diabetes, and central 
obesity (Kapoor et al., 2005; Tong et al., 2005; Wu and Eckardstein, 2003). This is in part 
because of the increased triglyceride and lipoprotein lipase uptake by adipocytes, causing 
central obesity and insulin resistance. The central obesity leads to increased peripheral 
conversion of T to estradiol by aromatase activity, further worsening this vicious cycle. 
Decreased serum levels of T are associated with a pro-inflammatory state with raised levels 
of inflammatory mediators like TNF-a and IL-1b, which can be improved with T 
substitution (Malkin et al., 2004). 
Besides its pro-atherogenic effects by altered lipid profile and insulin resistance, T has also 
direct effects on the vasculature. T causes coronary vasodilation and improves chronic stable 
angina in men (English et al., 2000). Androgen receptors have been found in the myocardium 
and may exert some of the effects of T on the cardiac remodeling and renin-angiotensin-
aldosterone system. T and other anabolic hormone deficiencies are associated with the severity 
of heart failure and increased mortality (Jankowska et al., 2006). T augments expression of heat 
shock protein 70 in cardiac myocytes, through which it may play an important role in 
preconditioning and protection against cardiac ischemia (Liu et al., 2006). 
Studies that demonstrated an association between low serum T levels and raised 
cardiovascular mortality in general excluded patients at high risk for cardiovascular disease 
or those with established cardiovascular disease. This association whether applies to 
subjects with established cardiovascular disease has not been defined. In a study of 930 men 
with angiographically proven coronary disease that were followed up for a mean duration 
of 7 years, a high prevalence of low T at baseline ranging from 17 to 24% was seen. 
Decreased serum T levels as defined by baseline serum T levels of <2.6 nmol/l were an 
independent predictor of vascular and all-cause mortality (Malkin et al., 2010). In a recent 
study, Ruige et al. (Ruige et al., 2010) have reviewed the literature on serum T levels and 
overall mortality up to 2009. They demonstrated an excess mortality in elderly men (>70 
years of age) who have a reduced T, which has been especially marked in studies since 2007.  
It is important to consider the limitations of observational studies in showing the associations 
between coronary   artery disease (CAD) and serum levels of endogenous androgens. These 
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studies have had extremely variable CAD endpoints (e.g., ultrasound- or postmortem- based 
diagnosis, unspecified cardiac events, morbid conditions such as myocardial infarction [MI] 
and angina, mortality, and the performance of angiography), heterogeneous study 
populations, and variable selection criteria. For instance, most CAD patients have been taking 
medications and have changed their lifestyle, factors which could affect them compared to 
controls. In some studies, allocation of poorly matched controls may be problematic in 
analysis. Among patients, the time interval from MI to sampling changed from 3 months to 
several years and has not been always standardized for diurnal rhythm of hormone levels. 
Also, in most of the studies, no adjustment has been made for confounding factors. For 
instance, the diagnoses of hyperandrogenemia in women and hypoandrogenemia in men were 
confounded by accompanying concurrent metabolic disorders, such as insulin resistance, 
obesity, impaired fibrinolysis, and dyslipidemia, which are frequently seen in chronic diseases, 
including CAD and lower serum levels of T (Eckardstein & Wu, 2003). 
3. Exogenous T in cardiovascular disease 
The long-term effects of exogenous T on incidence of coronary events have not been 
determined. However, few small studies demonstrated that therapeutic doses of T decreased 
the severity and frequency of angina pectoris and reversed electrocardiographic signs of 
myocardial ischemia. Webb et al. [Webb et al 1999] demonstrated that a single intravenous (IV) 
bolus of 2.3 mg T prolonged time to 1-mm ST segment depression by 66 seconds in 14 men 
with low plasma T levels and CAD. The plasma levels of T increased from 5.2 to 117 nmol/l,  
suggesting that this is a pharmacological action on the coronary vessels. These acute, direct 
pharmacological effects of T have been further investigated during coronary angiography. 
Administration of T over a 3-min period into the coronary arteries of 13 men with the 
diagnosis of CAD during coronary angiography at supra-physiological doses of 8 lmol/l, but 
not at the physiological doses of 8 nmol/l, cause coronary vessel diameter and blood flow to 
increase significantly at all four doses of T tested. These results have been also confirmed by a 
similar study of 14 men with CAD [Rosano ET 1999].  
T has been employed at either pharmacological doses to exert selective effects on 
haematopoeitic marrow, muscle, bone, or other salutary effects in men with various chronic 
diseases (Handelsman, 2005; Liu, 2004) or at physiological doses as androgen replacement 
therapy for men with disorders of the hypothalamo-pituitary-testicular axis (Handelsman, 
2005; Zitzmann & Nieschlag, 2000). Randomized placebo-controlled studies demonstrated 
that T employed to patients with chronic heart failure decreases systemic vascular resistance 
and improves both overall exercise capacity and cardiac output (Malkin et al., 2006; Pugh et 
al., 2003, 2004). Yet, effects on objective echocardiographic findings were little, suggesting 
that improvements could have been indirect through enhanced exercise endurance resulting 
from skeletal muscle or psychological effects. The effects of androgens on undamaged and 
damaged myocardium might be variable. One randomized placebo-controlled study 
demonstrated no deleterious effects on cardiac structure or function in 16 athletes after 8 
weeks of  200 mg nandrolone decanoate injections (Hartgens et al., 2003). Likewise, the 
effects of testosterone have not been tested to determine whether androgen activation by 
aromatization to estradiol and/or amplification by 5 α reduction influences effects of 
androgens on cardiac function.  Routine echocardiographic evaluation used in the above 
studies may not have sufficient sensitivity to determine subtle changes of myocardial 
function seen with drugs including androgens. 
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Androgens might exert cardiac effects through indirect mechanisms like in blood vessel 
disorders such as atherosclerosis, increased erythropoiesis, hyperviscosity, haematocrit, and 
hypertension. In addition, androgens might  exert direct effects on cardiac muscle and its 
function by the androgen receptor expressed in cardiac muscle.  In vitro studies of nonhuman 
cardiac myocytes demonstrated that T can decrease peak shortening times and action potential 
duration (hence altering repolarization) (Kimura et al., 1993). The direct effects of androgens 
on cardiac muscle have been less investigated (Sader et al., 2001). They are mostly based on 
case reports of cardiomyopathy in some androgen abusers on postmortem examinations 
(Sullivan et al., 1998). Some studies of anabolic steroid abuse indicate that androgen abuse in 
athletes may cause left ventricular hypertrophy, which may persist afterwards. Yet, several 
important limitations should be mentioned such as the lack of randomization, the confounding 
role of strength training, and self-selection. A study of testosterone and nandrolone (Chung et 
al., 2007) employed for 4 weeks demonstrated no adverse effects of androgens on non-invasive 
measures of cardiac function, which is consistent with a previous study using nandrolone for 8 
weeks (Hartgens et al., 2003). Despite these promising findings during short-term use, longer 
studies would be necessary to show the maintenance of such a safety profile for long term. 
Retrospective data of over 2000 elite athletes from the East German national sports doping 
program, who were taking high dose synthetic androgens and were regularly monitored 
medically showed no cardiovascular complications. However, hepatic and other complications 
were frequently reported (Franke & Berendonk, 1997).  
Previous work suggests that T may relieve symptoms in patients with angina pectoris and 
resolves post-exercise ST-segment depression in patients suffering from angina (Jaffe, 1977). 
Jaffe et al. (Jaffe, 1977) demonstrated that intramuscular T injection for 4 to 8 weeks in 50 
men, who had ST-segment depression after exercise, improved post-exercise ST-segment 
depression, compared with placebo. This work did not study mechanisms by which T 
reduced ST-segment depression. Although early studies suggested beneficial effects of T in 
patients with angina, these studies were not placebo-controlled, were not randomized and 
the diagnosis of coronary artery disease was not angiographically established. Furthermore, 
the study by Jaffe (Jaffe, 1977) investigated the effect of T only on post-exercise ST-segment 
depression. It did not provide any information on hemodynamic parameters and the time 
course of ST-segment depression. Furthermore, not all previous studies in patients with 
angina pectoris have used pure T and therefore have not investigated the effect of T by itself 
on cardiovascular physiology. Yue et al. (Yue et al., 1995) demonstrated that T exerts 
endothelium independent dilatation of isolated rabbit aorta and coronary artery. The 
authors indicated that this may depend on an effect of T on potassium channels and 
potassium conductance but not on ATP-sensitive potassium channels, and they 
demonstrated that this effect is neither mediated by a classic hormonal receptor nor is sex-
dependent (Yue et al., 1995). Experimental evidence indicates that T may have a potential 
beneficial effect on myocardial ischemia by playing a role in the regulation of coronary 
artery tone. 
Mechanisms of action proposed for the effects of T were vasodilation of coronary arteries or 
their collaterals and an increase in hemoglobin levels which improves oxygen-carrying 
capacity of blood. Yet, the vasoactive properties of T have not been reported until recently. 
The time elapsed to 1-mm ST-segment depression was reported to be prolonged after 
intravenous infusion of T. This indicates an acute anti-ischemic effect of T. The increase in 
heart rate- blood pressure product and heart rate  shown either at 1-mm ST-segment 
depression or at peak exercise may suggest a direct vasodilator effect of T on coronary 
circulation. However, heart rate and blood pressure at rest were similar before and after T 
www.intechopen.com
 
Testosterone Therapy and the Heart 
 
83 
employment. This suggests that a peripheral effect of T may not determine its anti-ischemic 
effect. The prolongation of time to 1-mm ST-segment depression observed is similar to that 
observed in women after acute employment of 17b estradiol, suggesting a similar effect of 
sex hormones in men and women (Rosano et al., 1993). Collins et al. (Collins et al., 1995) 
indeed demonstrated that intracoronary infusion of 17b-estradiol restores endothelium 
dependent vasodilatation in women but not in men, indicating a specific role of sex 
hormones on the cardiovascular system. The anti-ischemic effect of T reported might 
explain the cardio-protective effect of T substitution in men with hypotestosteronemia. In 
the present study, mostly the patients with lower testosterone benefited from testosterone 
employment (Rosano et al., 1999). 
A recent study has shown that ventricular functions are normal in men with idiopathic 
hypogonadotropic hypogonadism (IHH) and substitutive therapy has no effects on 
ventricular functions, however it may increase peak pulmonary artery pressure (PAP) in 
small amounts (Yaylali et al., 2010). This finding is in line with previous studies 
demonstrating normal left ventricular functions in IHH men (Baysan et al., 2007; Celik et al., 
2001; Hartgens et al., 2003). In addition, substitutive therapy had no effects on RV systolic or 
diastolic functions. This study found no evidence of clinically significant effects of the use of 
substitutive therapy on ventricular functions in the short term. However, substitutive 
therapy may increase PAP in small amounts which may be related to its vasoactive 
properties in the pulmonary vasculature. The younger normal even testosterone deplete 
heart is a totally different state than the diseased atherosclerotic or failing older heart. In this 
respect previous studies examined the effects of exogenous testosterone on the hearts of 
older men which were already affected by atherosclerosis or syndrome of heart failure. In 
contrast, this study investigated the ventricular functions in much younger hearts with no 
evidence of atherosclerosis or heart failure before and after substitutive therapy. 
It has been shown that 12 weeks of treatment with T in men with CHF was well tolerated, 
safe, and led to significant improvements in symptoms and physical capacity. Larger clinical 
trials are needed to evaluate the mechanism of action of T, beneficial effect and confirmation 
of its safety in selected patients (Lellamo et al., 2010). 
4. Effects of T on cardiovascular risk factors 
Several cross-sectional population studies have demonstrated statistically significant 
correlations between various cardiovascular risk factors and plasma levels of T, however the 
correlations were opposite in women and men. The plasma T levels in men were frequently 
found to have positive correlations with serum levels of HDL –C and  have inverse 
correlations with plasma levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, 
fibrinogen, total cholesterol, and PAI-1 (Hergenc et al., 1999; Tchernof et al., 1996; Tsai et al., 
2000). Yet, serum levels of T were found to have even stronger inverse correlations with 
BMI, waist-hip ratio (WHR), waist circumference, amount of visceral fat, insulin, serum 
levels of leptin, and free fatty acids. The correlations of T with the cardiovascular-disease 
risk factors except visceral fat and insulin lost their statistical significance after adjustment 
for obesity and insulin resistance (Hergenc et al., 1999; Tchernof et al., 1996; Tsai et al., 2000). 
These findings suggest that a low serum level of T is a component of the metabolic 
syndrome in eugonadal men, which is a cluster of cardiovascular risk factors such as 
obesity, hypertriglyceridemia, glucose intolerance or overt type 2 diabetes mellitus, low 
HDL-C, and arterial hypertension. Metabolic syndrome is considered a procoagulatory and 
an anti-fibrinolytic state. And insulin resistance plays an important role in its etiology. Thus, 
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the frequent association of high T levels with a more favorable cardiovascular risk factor 
profile in men perhaps does not reflect direct regulatory effects of T on lipoprotein 
metabolism and the hemostatic system. Some studies demonstrated the loss of these 
associations when serum levels of free T were used to correlate with lipids and other 
cardiovascular-disease risk factors instead of serum levels of total T were used. In 
agreement with these findings, a reduced number of CAG repeats in the androgen receptor, 
which facilitates its binding to T, was associated with decreased levels of leptin,  HDL-C, 
BMI, and  low body fat mass (Zitzmann et al., 2001, 2003). One reason for the discrepancy 
between the associations of endogenous T and the biological effects with various 
cardiovascular risk factors is the inhibitory effect of insulin on the production of SHBG so 
that insulin resistance results in low levels of SHBG and low levels of total T as a result. 
The association between increased risk of coronary artery disease and plasma testosterone 
levels has been attributed in part to the unfavorable effect of T on fibrinolysis and HDL 
cholesterol (Glueck et al., 1993; Jones et al., 1989; Sorva et al., 1988). Plasma levels of HDL 
cholesterol are higher in women than in men, and some studies indicate that T substitution in 
men causes a decrease in plasma levels of HDL cholesterol (Jones et al., 1989; Sorva et al., 
1988). Glueck et al. (Glueck et al., 1993) demonstrated that T correlates with tissue 
plasminogen activator, the major stimulator of fibrinolysis positively, and with fibrinogen and 
plasminogen activator inhibitor inversely. However, recent studies have demonstrated that 2-
month therapy with testosterone undecanoate had a beneficial effect on lipoprotein profiles in 
older men (Uyanik et al., 1997). Although there might be an effect of plasma T levels on pro-
thrombotic state, yet there is no epidemiological evidence showing an association between 
coronary artery disease and high testosterone levels (Uyanik et al., 1997). 
5. Effects of androgens on vascular reactivity  
T can exert vasodilatation or vasoconstriction via endothelium-independent or 
endothelium-dependent  mechanisms and by genomic or non-genomic modes of action. The 
variation in these findings appears to be due to differences in concomitant disease, species, 
gender, and, most importantly, the dosage of T given. The significant reduction in nitrate- 
induced (and hence endothelium-independent) dilatation of the brachial arteries in female-
to-male transsexuals taking high-dose androgens indicate these possible adverse effects 
associated with use of T (McCredie et al., 1998). In another study, castrated patients with 
prostate cancer had a greater flow-induced (i.e., endothelium-dependent) dilatation of 
brachial arteries compared to controls; however, the degree of nitroglycerin induced 
endothelium dependent vasodilatation did not differ between the two groups (Herman et 
al., 1997). In a study of 110 healthy men, a positive association between endothelium-
dependent as well as endothelial-independent vasodilatation and the numbers of CAG 
repeats in exon 1 of the androgen receptor gene was observed. Therefore, the greater the 
sensitivity to T, the less brachial arteries dilate in response to either administration of nitrate 
or increased blood flow (Zitzmann et al., 2001). In contrast to these studies, IV 
administration of T in acute interventional studies to male patients with CAD showed 
apparently beneficial vasodilatory effects of T.  Likewise, most in vitro studies with animal 
vessels and in vivo studies in monkeys and dogs of both sexes indicate that T induces 
beneficial effects on vascular reactivity. Intracoronary injections of acetylcholine caused a 
significant endothelium-dependent vasodilatation in ovariectomized female cynomolgus 
monkeys treated with T for 2 years compared to untreated animals. In contrast, 
endothelium-independent vasodilatation occurred in the two groups normally (Adams et 
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al., 1995). In dogs, T induced vasodilatation of coronary arteries by both endothelium-
dependent and -independent mechanisms (Chou et al., 1996; Costarella et al., 1996). In 
addition, the results of studies with isolated aortas and/or rings of coronary arteries from 
pigs, rats, and rabbits showed that T administration improved both endothelium-
independent and/or endothelium-dependent vascular responsiveness in both sexes (Chou 
et al., 1996; Costarella et al., 1996; Yue et al., 1995). Yet, it must be noted that all these studies 
used supra-physiological doses of T in the micro-molar range. Teoh et al. (Teoh et al., 2000) 
demonstrated a direct vasodilatory effect of T on porcine coronary artery rings when given 
at micro-molar concentrations. But no direct effect was observed when T given at nano-
molar concentrations. In contrast, physiological doses of T reduced the vasodilatory effects 
of calcium ionophores and bradykinin. Likewise, T impaired endothelium-dependent 
relaxation of aortic rings from rabbits that were either exposed to tobacco smoke or that 
were either made hypercholesterolemic. In addition, T inhibited the adenosine-mediated 
vasodilatation of rat coronary arteries (Ceballos et al., 1999; Farhat et al., 1995; Hutchison et 
al., 1997). The molecular and cellular mechanisms by which E2 and T regulate vascular tone 
are not well known. Evidence for and against endothelium-dependent or endothelium-
independent mechanisms has been found. Some studies indicate endothelial nitric oxide 
involvement (Chou et al., 1996; Costarella et al., 1996; Geary et al., 2000). The nitric oxide 
synthase inhibitor L-NMMA inhibited T-induced vasodilatation in the aortas of rats, the 
coronary arteries of dogs, and the cerebral arteries of rats. Yet, another study demonstrated 
no effect of L-NMMA on T-induced vasodilatation of rabbit coronary arteries and aortas 
(Yue et al., 1995). Likewise, Hishikawa et al. (Hishikawa et al., 1995) demonstrated that E2 
but not T stimulated in vitro expression of nitric oxide synthase in human aortic endothelial 
cells. It has been observed that T increases the response of coronary arteries to prostaglandin 
F2a (Farhat et al., 1995). Also, dihydro-T increases the density of thromboxane receptors in 
rats and guinea pigs (Masuda et al., 1995). Yet, results of some in vitro and in vivo animal 
studies suggest that pretreatment with the prostaglandin synthesis inhibitor indomethacin 
induced no effect on T-induced vasodilatation. The role of eicosanoids in mediating the 
actions of T on the arterial wall still remains controversial. It is unknown whether T 
regulates vasoreactivity by either non-genomic or genomic effects or both. Androgen 
receptor expression has been determined in rat endothelial cells and aortic smooth muscle 
cells. In human arterial cells expression of the androgen receptors has not been directly 
demonstrated. However, the association of endothelium-independent and endothelium-
dependent vasoreactivity with the CAG repeat polymorphism in the androgen receptor 
suggests some indirect evidence for the expression of the androgen receptor on vascular 
smooth muscle cells and endothelial cells, respectively (Zitzmann et al., 2003). Also, steroid 
hormones can regulate vascular tone by modulation of cell membrane channels (e.g., 
voltage-dependent, ATP-sensitive, and calcium-activated potassium channels) and by non-
genomic mechanisms that involve plasma membrane steroid receptors. Several observations 
indicate that T, especially at supra-physiological doses, modulates vascular tone via its 
secondary metabolites (e.g., E2) and/or non-genomic modes of action. Flutamide or 
cyproterone acetate, the androgen receptor antagonists did not reduce the effects of T on pig or 
rabbit coronary arteries (Teoh et al., 2000). The expression of aromatase in vascular endothelial 
cells (Harada et al., 1999) increases the possibility that T can be converted to E2 and T induces 
its vasoactive effects through stimulation of the estrogen receptors. Yet, neither the estrogen-
receptor antagonist ICI 182,780 nor the aromatase inhibitor aminogluthemide prevented the T-
induced vasodilatation (Chou et al., 1996). Barium chloride decreased the T-induced 
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vasorelaxation of rabbit coronary arteries and aortas, indicating that T modulates the opening 
of potassium channels in vascular smooth muscle cells.  
6. Conclusion 
The clinical picture of male hypogonadism carries a significant morbidity. After a careful 
diagnostic evaluation to identify the underlying cause of hypogonadism, substitutive therapy 
may be instituted after examining benefit to risk ratio for an individual patient. The clinician 
has a choice among different T preparations, tailoring pharmacokinetics and route of 
employment to the patient. Long-term effects of substitutive therapy on the cardiovascular 
system still remain unclear. Published data mostly consists of small, observational studies with 
no  clear definition of outcome. We still lack large randomized controlled studies investigating 
the relationship between substitutive therapy and cardiovascular risk, although androgen 
replacement therapy has been found to have beneficial effects on bone density, body 
composition, metabolism, and muscle strength in hypogonadal men. The effects of 
physiological doses of T on the lipid profile remain to be fully defined and the risk of not 
replacing T in the deficient men also remains unclear. Firstly, we might think that T and 
cardiovascular disease are clearly related, but the intricacies of the relationship are much more 
complex. As the role of androgens in cardiovascular system becomes clearer in the future, we 
may find out the mechanisms that play a role in the observed sex differences in the incidence 
of coronary artery disease in the middle-aged population. 
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